Navigation Links
Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
Date:10/14/2008

DURHAM, N.C., Oct. 10 /PRNewswire/ -- Regado Biosciences, Inc., announced today the Company has completed enrollment in the Phase IIa clinical study of its REG1 Anticoagulation System in patients undergoing elective percutaneous coronary intervention (PCI). REG1 is a two-component system composed of an aptamer-based anticoagulant, RB006, and its matched, active reversal agent, RB007, which specifically binds to and neutralizes RB006. The Phase IIa study (REVERSAL-PCI) is designed to assess whether REG1 can replace standard heparin therapy during the performance of coronary balloon angioplasty dilatation and stenting on patients at low risk for complications associated with therapy-related bleeding or heart attack.

REVERSAL-PCI, a multi-center, open-label, randomized clinical study, has enrolled a total of 26 patients. All patients were pretreated with clopidogrel and aspirin to inhibit platelet activity and were then randomized to receive either REG1 or unfractionated heparin. In patients treated with the REG1 System, RB006 was used as the sole anticoagulant during the procedure. Following the procedure, RB007 was used to reverse the effects of RB006 with the goal of facilitating early sheath removal. Primary procedural success in the trial is defined by the absence of significant bleeding events up to hospital discharge or 48 hours post stenting, and by the absence of death, nonfatal heart attack, or need to repeat revascularization up to day 14.

David J. Mazzo, Ph.D., President and Chief Executive Officer of Regado Biosciences, stated, "The Phase IIa trial is designed to build on extensive Phase I results demonstrating, among other things, that RB006 safely and effectively inhibited the activity of factor IXa, an essential blood clotting protein, and that RB007 rapidly, safely and specifically reversed the activity of RB006. We are pleased to have reached this milestone in our clinical program and look forward to continued progress in the comi
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
2. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
3. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
4. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
5. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
6. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
7. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
8. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
9. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
10. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
11. Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 2015 Quietly, sedately, Morocco,s pharmaceutical ... domestic pharmaceutical industry is strong, with a well-developed base ... international standards. One place where the quality ... Africa: Morocco has quietly become the second largest African ... . Indeed, Moroccan pharma companies have been making ...
(Date:7/31/2015)... SAN DIEGO , July 31, 2015 ... Eisai Co., Ltd. (Headquarters: Tokyo , ... Halozyme Therapeutics, Inc. (Headquarters: San Diego, California ... , "NASDAQ: HALO") have signed a clinical collaboration agreement ... , "eribulin") in combination with Halozyme,s investigational drug PEGPH20 ...
(Date:7/31/2015)... , July 31, 2015 ... solutions for video, data and cloud computing operators ... a leading pharma giant for Internet of Things ... IoT applications offered on subscription model. ... Pharma giant is striving for business innovations to ...
Breaking Medicine Technology:PharmaBoardroom Releases New Morocco Pharmaceuticals Report 2PharmaBoardroom Releases New Morocco Pharmaceuticals Report 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2
... YORK, Oct. 6, 2011 Reportlinker.com ... report is available in its catalogue: ... Market to 2017 - Patent Expiry ... Impact Dyslipidemia Market Value ...
... NEW YORK, Oct. 6, 2011 Reportlinker.com ... is available in its catalogue: ... http://www.reportlinker.com/p0254328/The-Future-of-European-Pharmaceutical-Distribution.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical ... to reduce internal costs for manufacturers, and ...
Cached Medicine Technology:Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 2Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 3Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 4Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 5Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 6Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 7Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 8Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 9Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 10Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 11Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 12Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 13Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 14Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 15The Future of European Pharmaceutical Distribution 2The Future of European Pharmaceutical Distribution 3The Future of European Pharmaceutical Distribution 4The Future of European Pharmaceutical Distribution 5The Future of European Pharmaceutical Distribution 6The Future of European Pharmaceutical Distribution 7The Future of European Pharmaceutical Distribution 8The Future of European Pharmaceutical Distribution 9
(Date:7/31/2015)... ... ... Girl Scouts of Historic Georgia and Peach State Health Plan are teaming ... Friend First" program. Representatives from Peach State Health Plan presented a $10,000 check for ... our parent company, Centene Corporation, are dedicated to raising anti-bullying awareness. We are very ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Like nearly ... techniques have also been advanced, upgraded, made more effective and less intrusive and painful. ... Loria Medical Penile Enlargement Center. Dr. Loria currently stands as the only doctor ...
(Date:7/31/2015)... ... July 31, 2015 , ... Florida ... novel catheter that was developed for targeted delivery of fluids to selected sites ... treated at Florida Hospital Tampa with the device that provides direct, local delivery ...
(Date:7/31/2015)... Rochester, N.Y. (PRWEB) , ... July 31, 2015 ... ... Brand, is proud to announce that their latest designer handbag line will be ... recently become an Internet sensation as the first globally recognized model with Down ...
(Date:7/31/2015)... ... July 31, 2015 , ... According to WFLA ... result of heroin use and eventual overdoses. Thricefold deaths have held steady over the ... handle on the Sarasota heroin epidemic, which was spurred by the crackdown of prescription ...
Breaking Medicine News(10 mins):Health News:Peach State Health Plan Presents $10,000 Check for “Be a Friend First” Anti-Bullying Program to Local Girl Scouts 2Health News:Loria Medical Penile Enlargement Center to Expand, Offering Practice Partnership to Doctors 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 4Health News:everMaya to Launch Madeline Stuart Handbag Line 2Health News:everMaya to Launch Madeline Stuart Handbag Line 3Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 3
... and ... Children,s Hospital Boston, BOSTON, April 8, 2008 Hess ... help support,children with medical needs through the Jimmy Fund and the ... every home run hit during a New,England Sports Network (NESN) televised ...
... Building Innovations, Products Help Protect and Preserve Buildings, ... DuPont (NYSE:,DD) and The Energy and Resources Institute ... the cause of green building design and,certification in ... Kalsi, president of DuPont India,and Dr. R. K. ...
... Distort State Funding, HARRISBURG, Pa., April 8, ... by more than $500 million in the past ... today expressed,continuing concern about misleading claims from nursing ... Pennsylvania,s nursing,home facilities., "Nursing home representatives seem ...
... PITTSBURGH, April 8, 2008 Precision Therapeutics ... it signed contracts with,National Preferred Provider Network ... NPPN, headquartered in Middletown, NY, is ... country representing more than seven million lives. ...
... at Events Nationwide Saturday, April 12, to Help ... 8, 2008 On Saturday, April 12, more than,600,000 ... Healthy,Kids(R) Day -- the nation,s largest health day for ... YMCA Healthy Kids Day encourages families,to "Put Play in ...
... Auctions off Flight Simulator Experience on eBay, ... one lucky guest in the captain,s seat in ... Cancer Society (ACS), United is auctioning off a,behind-the-scenes ... Flight Training Center in Denver, Colo., including two ...
Cached Medicine News:Health News:Every Boston Red Sox Home Run Televised on NESN in 2008 to Help Children With Medical Needs 2Health News:Every Boston Red Sox Home Run Televised on NESN in 2008 to Help Children With Medical Needs 3Health News:DuPont and TERI Sign Memorandum of Understanding on Green Building Design in India 2Health News:DuPont and TERI Sign Memorandum of Understanding on Green Building Design in India 3Health News:DuPont and TERI Sign Memorandum of Understanding on Green Building Design in India 4Health News:Precision Therapeutics Adds 8 Million Covered Lives Under Contract 2Health News:YMCA of the USA Celebrates 'YMCA Healthy Kids(R) Day,' the Nation's Largest Health Day for Children and Families 2Health News:YMCA of the USA Celebrates 'YMCA Healthy Kids(R) Day,' the Nation's Largest Health Day for Children and Families 3Health News:YMCA of the USA Celebrates 'YMCA Healthy Kids(R) Day,' the Nation's Largest Health Day for Children and Families 4Health News:YMCA of the USA Celebrates 'YMCA Healthy Kids(R) Day,' the Nation's Largest Health Day for Children and Families 5Health News:Be in the Captain's Seat in the Fight Against Cancer 2Health News:Be in the Captain's Seat in the Fight Against Cancer 3
... A necessary addition to ... the Reichert Trial Frame ... and smooth controls for ... robust design, high-quality materials, ...
... The Ultramatic Rx Master is ... years of reliable service and ... that measurably improve procedures. It ... need and want most, including ...
The Maverick Over-The-Wire balloon catheter delivers a new level of performance to meet the changing demands of interventional cardiology....
... Illumination is provided by a cool-running, ... light only what you need to see ... best of all they are maintenance free ... light bulb. Every Phoroptor comes with a ...
Medicine Products: